title: High levels of acetaldehyde in nonalcoholic liver injury after threonine or ethanol administration.
abstract: Acetaldehyde, a product of ethanol oxidation which forms adducts with proteins, has been incriminated in the pathogenesis of alcoholic liver injury. High serum antibody titers against acetaldehyde-protein adducts have been found not only in alcoholics but also in patients with nonalcoholic liver disease, suggesting a contribution of acetaldehyde derived from sources other than exogenous ethanol. To investigate the effect of liver injury on the removal and the production of acetaldehyde, we produced fibrosis and cirrhosis (by chronic administration of carbon tetrachloride) and fatty liver (with very small doses of dimethylnitrosamine) in rats. Endogenous blood acetaldehyde levels increased by 38% in rats with severe liver injury (p less than 0.005), but not significantly in rats with fatty liver. However, an i.v. load of threonine (a physiological source of acetaldehyde), in amounts equivalent to the daily intake of this amino acid, increased blood and hepatic acetaldehyde levels in the rats with both types of liver injury more than in controls. Threonine dehydrogenase and dehydratase activities, involved in the major pathways for threonine degradation in mitochondria and cytosol, respectively, were markedly decreased in rats with liver injury with a resulting increase in hepatic threonine concentration. Moreover, the threonine aldolase activity, which splits threonine into glycine and acetaldehyde, remained unaffected or even slightly increased. Liver injury was also associated with impaired mitochondrial functions, including a 10 to 23% decrease in acetaldehyde oxidation (depending upon the severity of the lesions). As a consequence, administration of ethanol (an exogenous source of acetaldehyde) resulted in striking elevations in the levels of acetaldehyde in carbon tetrachloride-treated rats.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Section of Liver Disease and Nutrition, Bronx Veterans Affairs Medical Center, New York, New York 10468.
authors.forename: X L
authors.initials: XL
authors.lastname: Ma
authors.forename: E
authors.initials: E
authors.lastname: Baraona
authors.forename: R
authors.initials: R
authors.lastname: Hernández-Muñoz
authors.forename: C S
authors.initials: CS
authors.lastname: Lieber
mesh_terms: D000079:Acetaldehyde / Q000097:blood / Q000378:metabolism*; D000429:Alcohol Oxidoreductases / Q000378:metabolism; D000818:Animals; D002251:Carbon Tetrachloride; D004128:Dimethylnitrosamine; D000431:Ethanol / Q000494:pharmacology*; D005234:Fatty Liver / Q000139:chemically induced / Q000378:metabolism*; D012696:Glycine Hydroxymethyltransferase / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008106:Liver Cirrhosis, Experimental / Q000139:chemically induced / Q000378:metabolism*; D008297:Male; D008930:Mitochondria, Liver / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D013912:Threonine / Q000378:metabolism / Q000494:pharmacology*; D013913:Threonine Dehydratase / Q000378:metabolism
chemical_list: D013912:Threonine; D000431:Ethanol; D002251:Carbon Tetrachloride; D000429:Alcohol Oxidoreductases; C023159:L-threonine 3-dehydrogenase; D012696:Glycine Hydroxymethyltransferase; D013913:Threonine Dehydratase; D000079:Acetaldehyde; D004128:Dimethylnitrosamine